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Introduction 
Streptococcus (S.) pneumoniae is a part of normal flora of 
nasopharynx, but can cause a variety of infections in the 
general population.1 Majority of these infections are non-
invasive, such as otitis media, but some invasive 
infections, like meningitis, bacteraemia and pneumonia, 
can be life-threatening.2 Invasive pneumococcal disease 
(IPD) is defined as an infection confirmed by the isolation 
of S. pneumoniae from a normally sterile site (e.g. blood 
or cerebrospinal fluid [CSF] but not sputum).3  
IPD, particularly meningitis, is associated with substantial 
rates of morbidity (20-30%) and mortality (10%).4-6  
Pneumococcal Global Burden of Disease Study Team 
concluded that Pakistan, among six other countries of 
Asia, has the highest number and proportion of S. 
pneumoniae cases.7-9 Changing trends in the 
antimicrobial susceptibility pattern of S. pneumoniae in 
invasive infections have been reported globally.10,11 There 
is an increase in the rate of resistance to various classes of 
antibiotics, especially β-lactams, which have traditionally 
been an effective therapy.10 This makes the treatment 
more difficult and costly. Resistance rates vary widely 
among different geographic regions. Published data from 
different countries reports variable prevalence of 
penicillin and ceftriaxone resistance amongst S. 
pneumoniae strains. For example, a study from South 
Africa revealed penicillin resistance in 33% of their 
invasive strains,12 while a centre in Baltimore, United 
States13 reported 48.6% penicillin-resistant strains. India, 
one of Pakistan's neighbouring countries, has reported 
just 2.7% penicillin resistance.14 Resistance to penicillin, 
ceftriaxone or any other third generation cephalosporin 
among invasive isolates of S. pneumoniae has not been 
documented yet in Pakistan.15 However, a recent study on 
pneumococcal nasal carriage showed penicillin minimum 
inhibitory concentration (MIC)90 of 0.25 mcg/ml, 
suggesting there are some strains circulating in the 
community which could be considered resistant using 
meningitic breakpoints.16 There is also paucity of IPD 
demographic and risk factor data reported from Pakistan. 
Therefore, the current study was planned to identify 
differences in demographic, co-morbid and other clinical 
parameters as well as antimicrobial susceptibility 
between meningitic and non-meningitic IPD strains. 
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Abstract 
Objective: To determine the resistance rate of penicillin and ceftriaxone amongst invasive meningitis and non-
meningitis isolates of streptococcus  pneumoniae. 
Methods: The prospective cross-sectional study was conducted from January 2011 to March 2014 at the Clinical 
Microbiology Laboratory of Aga Khan University, Karachi, and comprised all invasive strains of streptococcus 
pneumoniae. Penicillin and ceftriaxone susceptibilities were performed and interpreted based on minimum 
inhibitory concentration breakpoints recommended by Clinical and Laboratory Standards Institute guidelines. Data 
was analysed using Stata 12. 
Result: There were 163 strains isolated from sterile body fluids of 109 patients. Of the total, 46(28%) samples were 
meningitic while 117(72%) were non-meningitic. Of the meningeal isolates, 12(26%) were resistant to penicillin, 
while none was resistant to ceftriaxone and vancomycin. None of non-meningeal isolates showed resistance to 
penicillin, ceftriaxone or vancomycin. 
Conclusions: There was considerable penicillin resistance among meningeal strains of streptococcus pneumoniae, 
but here appeared to be no need to add vancomycin for empirical treatment of invasive streptococcus pneumoniae 
infection. 
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Materials and Methods 
The prospective cross-sectional study was conducted 
from January 2011 to March 2014 at the Clinical 
Microbiology Laboratory of Aga Khan University (AKU), 
Karachi. The laboratory receives specimens from patients 
admitted to AKU Hospital (AKUH), a tertiary care 700-bed 
private facility. In addition, the laboratory receives 
samples from more than 200 collection points spread all 
over the country. All invasive strains of S. pneumoniae, 
defined as those isolated from sterile body fluids, such as 
blood, CSF, pleural fluid, synovial fluid, ascitic fluid and 
splenic drain specimens, were included. S. pneumoniae 
strains from both CSF and blood cultures in the same 
patient were considered duplicates, and in that case, the 
CSF isolate was included for analysis. Multiple isolates 
from the same patient were also considered duplicates. 
All non-invasive S. pneumoniae strains and duplicate 
isolates were excluded. 
The sample size was calculated on the basis of a previous 
study17 which showed penicillin resistance of 44% and 
ceftriaxone 15% among invasive pneumococcal isolates. 
It was calculated using World Health Organisation (WHO) 
software,18 using lowest proportion, i.e. ceftriaxone 15%, 
and an absolute precision of 6%, at 95% confidence level.  
Clinical and demographic information on the patients 
was obtained via telephonic communication with 
respective clinicians. It was collected as part of routine 
clinical reporting of cultures at the AKU laboratory, and 
was retrieved from laboratory records. No additional 
information was obtained. S. pneumoniae isolates were 
considered meningitic if they were isolated from CSF. In 
case of blood culture isolates, only those from patients 
who had a clinical diagnosis of meningitis were 
considered meningitic. In case of growth of S. 
pneumoniae from both CSF and blood samples of the 
same patient, preference of susceptibility was given to 
the CSF isolate. Exemption from ethical approval was 
obtained from the institutional ethics review committee. 
Clinical isolates of S. pneumoniae were identified using 
American Society of Microbiology (ASM) guidelines.19 
Initial suspicion of pneumococcus was based on centrally 
depressed colony morphology, i.e.  Draughtsman colony, 
α-haemolysis, gram staining and catalase test. Final 
identification was confirmed by conventional tests, such 
as optochin and bile salt susceptibility. Fresh isolates of S. 
pneumoniae growing on enriched media were initially 
saved at -80°C in 1ml aliquots containing glycerol-
phosphate buffer.  
Susceptibility testing of antibiotics recommended by 
Clinical and Laboratory Standards Institute (CLSI) 
guidelines,20 including vancomycin, chloramphenicol, 
were performed using Kirby-Bauer disk diffusion method. 
For testing penicillin and ceftriaxone MICs, organisms were 
revived on the sheep blood (SB) agar. To perform 
susceptibilities, 0.5 McFarland suspension was made, sterile 
swab dipped in the suspension was squeezed to remove 
the excess fluid, and lawn was made on Mueller-Hinton agar 
(MHA) with 5% sheep blood (SB-MHA). E-test strip of 
penicillin (Oxoid) and ceftriaxone (Biomerieux) were placed 
over the lawn on two separate 90mm SB-MHA plates 
incubated in 5% carbon di-oxide (CO2) enriched 
atmosphere for 24h. MICs were read and interpreted 
according to CLISI breakpoints20 and the isolate was 
categorized as sensitive (S), intermediate (I) or resistant (R). 
In the 21st Informational Supplement of CLSI, the 
recommended MIC breakpoints of penicillin and 
ceftriaxone are different for S. pneumoniae isolates growing 
from meningeal CSF and other invasive non-meningeal 
isolates.20 For meningeal strains, penicillin MIC <0.06μg/ml 
isolate is considered susceptible while MIC of >0.12 μg/ml is 
categorised as resistant. For non-meningeal isolates, 
penicillin MIC of 2μg/ml, 4μg/ml and 8μg/ml is regarded as 
S, I and R, respectively. Similarly, for meningeal isolates, 
ceftriaxone MIC of <0.5 μg/ml, 1μg/ml and >2μg/ml are 
defined as S, I and R. Finally, MIC of 1 μg/ml, 2μg/ml and 
4μg/ml are categorized as S, I and R, respectively for non-
meningeal ones. Multidrug-resistance (MDR) was defined as 
penicillin (beta-lactam) resistance along with resistance to 2 
or more antibiotics from among co-trimoxazole, ofloxacin, 
erythromycin and chloramphenicol.12 CSF isolates were 
tested against ofloxacin, erythromycin and tetracycline only 
for categorisation as MDR or non-MDR, and these antibiotics 
were not reported for clinical use. 
Data was coded and entered into Microsoft Excel 2010, 
transferred to Stata 12 software for statistical analysis. 
Mean and standard deviation of the continuous variables, 
i.e. age, and penicillin and ceftriaxone MICs, were 
calculated. Frequency and percentage of the categorical 
variables, like age group, gender, source of specimen, 
antibiotic susceptibility, clinical information on prior 
antibiotic history and vital status, was also calculated. 
Fischer's exact test was used to determine whether there 
was any statistically significant difference between the 
meningitic and non-meningitic isolates in terms of 
susceptibility profile and clinical characteristics. Binary 
logistic regression was used to calculate odds of mortality 
in the presence of certain risk factors by performing 
univariate and then multivariable analysis. 
Results 
There were 163 strains isolated from sterile body fluids of 
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Table-1: Minimum inhibitory concentration (MIC) and susceptibility data of meningitic and non-meningitic isolates of Streptococcus pneumoniae (N=163). 
 
Beta-lactam drugs MIC                                                                                                          Meningitic (n=46)                                                                             Non-meningitic (n=117) 
 
Penicillin                                                                                                                                                                                                                                                                               
MIC50                                                                                                                                                  0.06 μg/ml                                                                                                  0.03 μg/ml 
MIC90                                                                                                                                                0.125 μg/ml                                                                                                 0.25 μg/ml 
Ceftriaxone                                                                                                                                                                                                                                                                           
MIC50                                                                                                                                                0.032 μg/ml                                                                                                0.023 μg/ml 
MIC90                                                                                                                                                0.094 μg/ml                                                                                                0.094 μg/ml 
 
Antibiotics                                                                                     No. of resistant (R)                                                                          No. of resistant (R)                                                                         Fisher's exact 
(no. tested)                                                                               meningitic strains, %R                                                              non-meningitic strains, %R                                                                     (p-value) 
 
 Penicillin (n=163)                                                                           12/46, 26.09                                                                                          0/117, 0                                                                                        <0.001* 
Ceftriaxone (n=163)                                                                             0/46, 0                                                                                                0/117, 0                                                                                                - 
Ofloxacin (n=159)+                                                                         8/42, 19.05                                                                                        8/117, 6.84                                                                                       0.022* 
Chloramphenicol  (n=159)                                                             6/42, 14.29                                                                                        5/117, 4.27                                                                                        0.069 
Erythromycin (n=159)+                                                                12/42, 28.57                                                                                     29/117, 24.79                                                                                     0.361 
Tetracycline (n=159)+                                                                  20/42, 47.62                                                                                     59/117, 50.43                                                                                    0.033* 
Co-trimoxazole (n=159)+                                                            31/42, 73.81                                                                                     97/117, 82.91                                                                                     0.336 
Vancomycin (n=159)                                                                           0/42, 0                                                                                                0/117, 0                                                                                                - 
MDR (n=159)                                                                                      8/42, 19.05                                                                                           0/117, 0                                                                                        <0.001* 
 
MIC: Minimum inhibitory concentration, R: Resistant. MDR: Multi-drug resistent. 
+These antibiotics are not used for treatment of meningitis and the resistance rates given here are only of epidemiological significance. *Statistically significant at p-value <0.05.
Table-2: Descriptive statistics: clinical differences between meningitic and non-meningitic streptococcus pneumoniae strains in 109 patients admitted in Aga Khan University Hospital. 
 
Risk Factor                                                                                            Meningitic (N=31) (N, %)                                     Non-meningitic(N=78) (N, %)                                                 Fisher's exact p-value 
 
Age Group                                                                                                                                                                                                                                                                                                              0.003* 
<5                                                                                                                            6, 19.4                                                                              24, 30.8                                                                                            
>5 to <15 years                                                                                                  7, 22.6*                                                                              2, 2.6*                                                                                              
>15 to <64 years                                                                                                8, 25.8                                                                              35, 44.9                                                                                            
>65 years                                                                                                              10, 32.3                                                                             17, 21.8                                                                                            
Male gender                                                                                                         19, 61.3                                                                             41, 52.6                                                                                      0.523 
Diabetes                                                                                                                  4, 12.9                                                                              17, 21.8                                                                                       0.42 
Hypertension                                                                                                         4, 12.9                                                                              13, 16.7                                                                                      0.774 
COPD                                                                                                                         2, 6.5                                                                                 4, 5.1                                                                                             1 
Renal disease                                                                                                           0, 0                                                                                   1, 1.3                                                                                             1 
Cancer                                                                                                                       1, 3.2                                                                                 4, 5.1                                                                                             1 
Liver disease                                                                                                             0, 0                                                                                 12, 15.3                                                                                     0.018* 
Smoker                                                                                                                     1, 3.2                                                                                 3, 3.8                                                                                             1 
Hospital Unit                                                                                                                                                                                                                                                                                                           0.474 
Ward                                                                                                                       17, 56.7                                                                             51, 68.0                                                                                            
ICU                                                                                                                             5, 16.7                                                                               8, 10.7                                                                                              
ER                                                                                                                              8, 26.7                                                                              16, 21.3                                                                                            
Pneumonia                                                                                                            7, 22.6                                                                              57, 73.1                                                                                   <0.001* 
Death                                                                                                                       7, 22.6                                                                              11, 14.1                                                                                      0.391 
Antibiotic Therapy 
Vancomycin                                                                                                          12, 41.4                                                                             13, 18.3                                                                                     0.022* 
3rd Gen Cephalosporin                                                                                      14, 48.3                                                                             41, 56.9                                                                                       0.51 
Ampicillin                                                                                                                   0, 0                                                                                   6, 8.3                                                                                        0.178 
Carbapenem                                                                                                          6, 20.7                                                                                5, 6.9                                                                                       0.073* 
Betalactam-inhibitor combination                                                                 6, 20.7                                                                              11, 15.3                                                                                      0.561 
Macrolides                                                                                                              4, 13.8                                                                              12, 16.7                                                                                          1 
 
*Statistically significant difference between the meningitic and non-meningitic strains. *Statistically significant at p-value <0.05. NS: Not significant. 
In multivariable analysis, male gender, admission in ICU and emergency room had higher odds of mortality while erythromycin resistance was found to be protective against it, after adjusting for age groups. 
ICU: Intensive care unit. ER: Emergency room.
109 patients. Of the total, 46(28%) samples were 
meningitic while 117(72%) were non-meningitic. Among 
the patients, 57(52.3%) had presented with signs and 
symptoms of pneumonia alone, 24(22%) with meningitis 
alone, 7(6.4%) with both pneumonia and meningitis, and 
21(19.2%) had neither pneumonia nor meningitis 
symptoms. In terms of age, 30(27.5) patients were 5 years 
or younger, 9(8.25%) were aged 5-15 years, 43(39.4%) 
were 15-65 years and 27(24.7%) >65 years. Overall, 
60(55%) patients were male. 
Of the 46 meningitic isolates, 23(50%) grew from CSF 
samples, and, in 19(82.6%) of them, S. pneumoniae were 
yielded only from CSF samples, while in 4(17.4%) cases, 
both CSF and blood yielded the same isolate. In the 
remaining 23(50%) cases, isolates grew from blood 
cultures, and, based on clinical suspicion, these isolates 
were considered meningitic. Among the 46 meningitic 
isolates, 42(91.3%) belonged to patients from Karachi, 
and, of them, 24(57%) patients were hospitalised at 
AKUH. Only 4(8.6%) samples were received from other 
cities of Pakistan.  
At AKUH, 7(29%) patients were admitted in intensive 
care unit (ICU), while 17(71%) were treated in general 
wards. In the 24 in-patients, empirical ceftriaxone was 
started in 14(58%) patients, and 5(36%) of them were 
given the drug alone and 9(64%) in combination with 
other drugs. Besides, 10(42%) patients received other 
broad-spectrum beta-lactam antibiotics; 7(70%) 
meropenem and 3(30%) piperacillin-tazobactam. In 
15(62.5% patients, vancomycin was added along with 
ceftriaxone, meropenem or piperacillin-tazobactam. Of 
the 24 patients at AKUH, 6(25%) died in hospital, 
8(33%) were discharged and 10(42%) were transferred 
to other facilities. No clinical history was available in 
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Table-3: Predictors of mortality: binary logistic regression -univariate and multivariable analysis. 
 
Risk factor                                                                                          Expired (N, %)                                                   Univariate OR, CI (p-value)                                   Multivariable analysis OR, CI (p-value) 
 
Male                                                                                                           20, 33.3                                                                3.6, 1.3-9.8 (0.01)*                                                          5.3, 1.5-18.7 (0.009)* 
Female                                                                                                       6, 12.2                                                                                                                                                                                       
Age group                                                                                                                                                                                                                                                                                                      
>15y to <64y (reference)                                                                  10, 38.5                                                                                                                                                                                      
<5y                                                                                                              9, 34.6                                                                  1.4, 0.5-4.1 (0.52)                                                            2.7, 0.65-11.3 (0.17) 
>5y to <15y                                                                                               0, 0                                                                                      -                                                                                                 - 
>65y                                                                                                           7, 26.9                                                                  1.2, 0.4-3.5 (0.80)                                                               1.3, 0.3-4.9 (0.69) 
Cancer                                                                                                        3, 60.0                                                                5.3, 0.8-33.5 (0.08)*                                                                           NS 
Non-cancer                                                                                              23, 22.1                                                                                                                                                                                      
Hospital Unit                                                                                                                                                                                                                                                                                                 
Ward (reference)                                                                                     9, 13.2                                                                                                                                                                                       
ICU                                                                                                               6, 46.2                                                               5.6, 1.5-20.5 (0.009)*                                                       6.1, 1.2-28.4 (0.022)* 
ER                                                                                                                10, 41.7                                                              4.6, 1.9-13.7 (0.005)*                                                       5.0, 1.4-18.3 (0.014)* 
Antibiotic Resistance                                                                                                                                                                                                                                                                                  
Penicillin                                                                                               0,0 vs. 4, 4.8                                                                              -                                                                                                  
Ofloxacin                                                                                          1, 3.9 vs. 11, 13.3                                                        0.3, 0.0-2.0 (0.19)                                                                                  
Chloramphenicol                                                                             1, 3.9 vs. 7, 8.4                                                          0.4, 0.1-3.7 (0.45)                                                                                  
Erythromycin                                                                                  2, 7.7 vs. 28, 33.7                                                       0.2, 0.0-0.7 (0.02)*                                                          0.1, 0.02-0.7 (0.017)* 
Co-trimoxazole                                                                           21, 80.8 vs. 69, 83.1                                                      0.7, 0.2-2.3 (0.59)                                                                                  
Tetracycline                                                                                  11, 42.3 vs. 52, 62.7                                                    0.4, 0.2-1.0 (0.06)*                                                                             NS 
MDR                                                                                                       0,0 vs. 4, 4.8                                                                              -                                                                                                  
Antibiotic Therapy (n, %)                                                                                                                                                                                                                                                                         
Vancomycin                                                                                   8, 32.0 vs. 17, 22.7                                                       1.6, 0.6-4.3 (0.35)                                                                                  
3rd Gen Cephalosporin                                                             13, 50.0 vs. 42, 56.0                                                      0.7, 0.3-1.9 (0.60)                                                                                  
Ampicillin                                                                                          2, 7.7 vs. 4, 5.3                                                          1.5, 0.3-8.6 (0.66)                                                                                  
Carbapenem                                                                                    5, 19.2 vs. 6, 8.0                                                        2.7, 0.8-9.9 (0.12)*                                                                             NS 
Betalactam-inhibitor combination                                        3, 11.5 vs. 14, 18.7                                                       0.6, 0.1-2.2 (0.41)                                                                                  
Macrolides                                                                                     3, 11.5 vs. 13, 17.3                                                       0.6, 0.2-2.4 (0.49)                                                                                  
De-escalation in<3 days                                                         23, 88.5 vs. 65, 78.3                                                      2.1, 0.6-7.9 (0.26)                                                                                  
 
OR: Odds ratio 
CI: Confidence interval 
ICU: Intensive care unit 
ER: Emergency room.
meningitis patients whose samples were submitted as 
outpatients. 
Out of the 46 meningeal strains, 12(26 %) isolates were 
found resistant to penicillin with MIC50= 0.046 μg/ml and 
MIC90= 0.125 μg/ml. None of them was resistant to 
ceftriaxone with MIC50= 0.023 μg/ml and MIC90= 0.094 
μg/ml. Chloramphenicol resistance was found in 6(14.3%) 
isolates. 
Out of 117 non-meningitic IPD strains, 100(85.5%) were 
isolated from blood cultures, while the remaining 
17(14.5%) were from other sterile sites. None of non-
meningeal IPD isolates showed resistance to penicillin, 
ceftriaxone or vancomycin. Penicillin and ceftriaxone 
MICs of meningitic and non-meningitic isolates were 
compared and it was noted that penicillin resistance, 
and, hence, multi-drug resistance (MDR), was seen only 
in meningitic isolates (p<0.001). Ofloxacin resistance 
was significantly low, while tetracycline resistance was 
high in meningitic isolates, suggesting that the strains 
causing meningitis were different from non-meningitic 
ones, and, hence, serotypes could also be different 
(Table-1). 
Underlying liver disease, absence of pneumonia, 
vancomycin and carbapenem usage and age 5-15 years 
were significantly associated with meningitic strains 
(p<0.05 each) (Table-2).  
After adjusting for age, patients presenting to emergency 
department (ED) requiring ICU admission and having 
male gender were found to have higher odds of mortality 
than female patients who were neither admitted through 
ED nor ended up in ICU; and erythromycin resistance 
appeared to be protective against mortality (Table-3), 
suggesting that strains isolated from patients who 
expired were less likely to be exposed to macrolides, 
which are the first-line antibiotics used in respiratory tract 
infections. 
Discussion 
The current laboratory-based study clearly indicates that 
penicillin resistance was high (26%) amongst meningitic 
S. pneumoniae isolates from Karachi. However, 
ceftriaxone resistance was not detected in any of these 
tested isolates. On the other hand, regional data from 
India and Bangladesh has reported very low percentage 
of penicillin non-susceptible isolates in studies ranging 
from 1.3 to 2.9.12,20 Regarding ceftriaxone non-
susceptibility, international data again shows wide 
variation.21-24 In Pakistan surveillance data for 
susceptibility of invasive S. pneumoniae isolates is limited. 
The current study comprised highest number of 
meningitis-causing S. pneumoniae isolates analysed for 
susceptibility pattern. A previous community-based study 
evaluated 15 strains of S. pneumoniae from Karachi and 
Hyderabad, and the susceptibility of S. pneumoniae to 
penicillin was 26% which is consistent with our findings. It 
also corroborates the available antibiogram data 
published by different tertiary care centres of Karachi, 
reporting penicillin resistance ranging 8-30% during 
2006-12.25  
Current recommendations by international guidelines 
prescribe a combination of ceftriaxone and vancomycin 
as empiric antibiotic therapy for suspected bacterial 
meningitis in all age groups except neonates.26 These 
guidelines are closely followed at the AKUH and the data 
as such indicates that 63% (15/26) of patients admitted 
in our setting were empirically started on IV vancomycin 
along with either ceftriaxone or other broad-spectrum 
antibiotics i.e. meropenem or piperacillin-tazobactam. 
Out of 46 isolates, 12(26%) revealed resistance to 
penicillin and justified the need of empiric ceftriaxone in 
cases of suspected bacterial meningitis. However, all of 
the meningitis-causing S. pneumoniae strains revealed 
ceftriaxone MIC within susceptible range with MIC50 
and MIC90 of 0.023, 0.094 μg/ml respectively. This 
collection had isolates with penicillin MIC90 of 
0.125μg/ml which further supports sole use of 
ceftriaxone in our setting. Therefore, our finding points 
out the overuse of empiric vancomycin for S. 
pneumoniae meningitis. 
In addition to AKUH hospitalised patients, 43% (20/46) of 
the tested S. pneumoniae isolates were from samples that 
were submitted from different areas of Karachi. This 
finding further highlights the susceptibility pattern of 
common strains circulating in the community. 
Looking at age and gender distribution, S. pneumoniae 
meningitis was found to be common in all age groups 
with almost 30% of cases occurring in <5 years of age. 
This study supports the need of vaccination in this age 
group. 
Male gender and severe disease necessitating ED 
presentation and ICU stay were significantly associated 
with patient demise even after adjusting for age as 
confounder. This emphasises the role of early disease 
recognition and timely institution of appropriate 
antibiotic therapy. The study has its limitations. For 
instance, the data is four years old and the majority of S. 
pneumoniae isolates belonged to Karachi city. Only four 
clinical samples belonged to other cities of Pakistan; 2 
from Hyderabad and one each from Quetta and 
Abbottabad. Although all four S. pneumoniae isolates 
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belonging to three different cities of Pakistan were 
susceptible to ceftriaxone, due to a small number of 
isolates this statement cannot be generalised for the 
whole of Pakistan. Due to cost constraints, the study 
could not to identify pneumococcal serotypes which 
could have helped in the selection of future vaccine type 
in Pakistan.  
For a wider and clearer picture, countrywide evaluation 
of S. pneumoniae susceptibility data using standard 
sensitivity testing methods is required and needs to be 
reported from other centres of Pakistan. Key role of 
antibiotic stewardship must be emphasised for the 
control of antimicrobial resistance. In this regard active 
participation of clinical microbiology laboratory is 
crucial. Prompt reporting of antimicrobial susceptibility 
is essential to curtail overuse of broad-spectrum 
antibiotics, including vancomycin. In 15 AKUH-
hospitalised patients, initial empiric therapy included 
vancomycin, but de-escalation of vancomycin within 3 
days was seen in all cases. In the 3 remaining patients, 
discontinuation of vancomycin was performed at 5th, 
6th and 10th days. Similarly, correct methodology to 
detect penicillin and ceftriaxone resistance is an 
essential requirement for correct reporting. CLSI 
recommends broth or agar dilution-based MIC reporting 
for penicillin, and ceftriaxone for meningeal S. 
pneumoniae strains as disk diffusion-based Kirby Bauer 
oxacillin screening method lacks sensitivity for detecting 
penicillin resistance in meningeal strains. Therefore, to 
minimise reporting errors, clinical laboratories should 
strictly follow this recommendation. We performed E-
strip testing for penicillin and ceftriaxone MIC 
determination. E-strip method is an easy, reliable and 
widely used method in clinical studies.26,27 Finally, in 
order to strictly monitor emerging resistance, sharing of 
resistance data amongst different hospitals is also 
required. 
Conclusion 
Penicillin resistance was found to be high in S. 
pneumoniae meningitis isolates from Karachi, justifying 
the empiric use of ceftriaxone. However, resistance to 
ceftriaxone was not found which suggests that the 
addition of vancomycin in empiric therapy of 
pneumococcal meningitis is currently not required. 
Continuous monitoring of antimicrobial susceptibilities is 
necessary by clinical laboratories to capture any emerging 
ceftriaxone resistance. Countrywide surveillance 
programme, including pneumococcal serotyping, is 
urgently needed to support curtailing of invasive 
pneumococcal disease. 
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